Michael Kassardjian, DO; Mayha Patel, DO; Paul Shitabata, MD; David Horowitz, DO
Drs. Kassardjian, Patel, and Horowitz are from Western University of Health Sciences, Pomona, California, and the Department of Dermatology, Pacific Hospital of Long Beach, California. Dr. Shitabata is from the Department of Dermatology, Harbor-UCLA Medical Center, Torrance, California.
The authors report no conflict of interest.
Correspondence: Michael Kassardjian, DO, 23550 Hawthorne Blvd, Ste 200, Torrance, CA 90505 (MichaelKassardjian@gmail.com).
The actual incidence of CSHR may be notably underreported due to its spontaneous regression and low rate of clinical recognition. A subtype of LCH, CSHR is a diagnosis of exclusion. Although CSHR generally follows a benign clinical course, a thorough workup and evaluation for systemic disease with close follow-up is recommended after diagnosis due to the potential of LCH to involve multiple organs and to relapse at a later date after apparent regression.
